Inhibition of SIRT2 enhances could enhances CD4+TSCM cells response by activating b-catenin, and finally enhances the BCG vaccine efficacy during primary infection and TB recurrence (Bhaskar et al., 2023). Here, CD4 is linked to tuberculosis.